Cardinal Health Stock Loses $912 Million as Recall Searches Test a $63.7 Billion Quarter - TechStock²
Article excerpt
Highlighted: the sentence this signal was extracted from
DUBLIN, Ohio, August 13, 2026, 15:30 EDT - U.S. equity markets were open. Cardinal Health, Inc. NYSE:CAH lost about $912 million in market value Thursday. Its shares fell 1.67% while the S&P 500 gained 0.73%. The drop coincided with more than 50,000 Google searches for "levothyroxine recall 2026." The recall includes tablets distributed under Cardinal Health labels. Timing alone does not show that the recall caused the share move. Google Trends The investor angle is scale. Cardinal generated $63.67 billion of quarterly revenue. The recalled lots matter for patients and quality controls, but no direct financial impact has been disclosed. CAH traded at $230.24 at 3:21 p.m. EDT. The session range was $229.36 to $235.67. Volume of 1.33 million shares remained below its 2.24 million average. The FDA classified the nationwide recall as Class II. Major Pharmaceuticals initiated it July 13 because some tablets may be subpotent. Certain unit-dose packs carried Cardinal Health labels. Patients should contact a pharmacist or clinician before changing therapy. Abruptly stopping levothyroxine can be riskier than temporarily taking a weaker tablet. The affected strengths and lots are listed in the FDA enforcement record. Cardinal's earnings picture is much larger. Fourth-quarter adjusted profit reached $2.91 a share, including a $0.31 tariff refund. Excluding that item, $2.60 still beat...
Keep reading with a free account
The rest of this article, and every signal for Cardinal Health, is in your free account.
